{
    "url_original": "https://www.wsj.com/articles/eli-lilly-asks-fda-to-approve-alzheimers-drug-11635262324?mod=business_lead_pos11",
    "url": "eli-lilly-asks-fda-to-approve-alzheimers-drug-11635262324",
    "title": "Eli Lilly Asks FDA to Approve Alzheimer’s Drug",
    "sub_head": "Drugmaker begins process seeking approval to sell donanemab as treatment for early-stage Alzheimer’s",
    "category_1": "Business",
    "category_2": "Health Care",
    "image_1_url": "https://images.wsj.net/im-423589?width=860&height=573",
    "image_1": "im-423589.jpg",
    "time": "2021-10-26 11:32:00",
    "body": "Eli Lilly  & Co. has begun asking U.S. health regulators to approve a new treatment for early-stage Alzheimer’s disease, hoping for a rare victory against a disease that has proved difficult for the pharmaceutical industry to tackle.<br />Indianapolis-based Lilly said Tuesday it began filing a rolling submission of study data and other information to the Food and Drug Administration for the experimental drug, donanemab."
}